BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng L, Ren W, Xie L, Li M, Liu J, Hu J, Liu BR, Qian XP. Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. Cancer Chemother Pharmacol 2014;74:1-13. [PMID: 24916545 DOI: 10.1007/s00280-014-2489-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
2 Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, Yang TS. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget 2016;7:22257-70. [PMID: 26989027 DOI: 10.18632/oncotarget.8076] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 13.8] [Reference Citation Analysis]
3 Ying HQ, Wang F, Chen XL, He BS, Pan YQ, Jie C, Liu X, Cao WJ, Peng HX, Lin K, Wang SK. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. Oncotarget 2015;6:28071-83. [PMID: 26363448 DOI: 10.18632/oncotarget.4872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Chen HK, Wang X, Wan YL, Tang JQ. Crosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells. Cancer Biol Ther 2019;20:454-60. [PMID: 30462558 DOI: 10.1080/15384047.2018.1529123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Geng F, Wang Z, Yin H, Yu J, Cao B. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biother Radiopharm 2017;32:149-60. [PMID: 28622036 DOI: 10.1089/cbr.2017.2210] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
6 Shan ZZ, Chen PN, Wang F, Wang J, Fan QX. Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis. Oncol Lett 2017;14:2859-63. [PMID: 28927043 DOI: 10.3892/ol.2017.6526] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
7 Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015;125:4529-4543. [PMID: 26571401 DOI: 10.1172/jci82826] [Cited by in Crossref: 70] [Cited by in F6Publishing: 50] [Article Influence: 10.0] [Reference Citation Analysis]
8 Zhang X, Song W, Zhou Y, Mao F, Lin Y, Guan J, Sun Q. Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. Oncol Lett 2017;13:2161-8. [PMID: 28454376 DOI: 10.3892/ol.2017.5726] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
9 Hu J, Zhang Z, Zheng R, Cheng L, Yang M, Li L, Liu B, Qian X. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis. Cancer Chemother Pharmacol 2017;79:275-85. [PMID: 27878357 DOI: 10.1007/s00280-016-3196-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Cheng L, Xia Z, Bian X, Li G, Hu J, Cao Y, Wang Q, Qian X. Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. Onco Targets Ther 2015;8:3185-92. [PMID: 26586952 DOI: 10.2147/OTT.S82453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]